Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(41)
•••
Comment by polygraph46on Mar 25, 2020 12:35am
139 Views
Post# 30844324

RE:Deal

RE:DealSKL, re deal, agreed as well, from my corner, it couldn't be worse.  I've been long on this play for quite a while.  Now, when I think back about the news releases over the past two years, I should have seen this day coming.  What, with the endless dilution.... as result of share issuance to Salzman(payment).... private placement..... Kaly bought Talent....balance owing, and on and on it goes.  Theres a consistent theme in all of those releases.........
All the while, Farrell is touting superb results on phase one and phase two.  And this....where he states in an Aug.2019 release....."we will proceed directly to initiate a phase 3 clinical registration study"(GVHD).  And now, the proposed share consol. buying Stero....we've been done.
Like you, I haven't sold a share.  If it gets to 0.04(I'm not holding my breath)...I am bailing as I see a continuance oflittle more than grasping at straws..........pg46
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities